Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review.

ABSTRACT:

Background

The coronavirus disease 2019 (COVID-19) pandemic has been a global health emergency since December 2019, leading to millions of deaths worldwide and placing significant pressures, including economic burden, on individual patients and healthcare systems. As of February 2022, remdesivir is the only US Food and Drug Administration (FDA)-approved treatment for severe COVID-19. This systematic literature review (SLR) aimed to summarise economic evaluations, and cost and resource use (CRU) evidence related to remdesivir during the COVID-19 pandemic.

Methods

Searches of MEDLINE, Embase the International Health Technology Assessment (HTA) database, reference lists, congresses and grey literature were performed in May 2021. Articles were reviewed for relevance against pre-

SUBMITTER: Murton M 

PROVIDER: S-EPMC9555695 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature